Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Warfarin in Idiopathic Pulmonary Fibrosis
NCT00957242Phase 3Terminated
- Sponsor
- Duke University
- Start
- Oct 2009
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Warfarin with Placebo (2 arms). Primary endpoint: Time to Death, Non-bleeding/Non-elective Hospitalization, or >10% Drop in Forced Vital Capacity at 48 weeks. Started Oct 2009; status: terminated.
02
Drugs
warfarin
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT00957242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00957242.